Covidien Launches Nellcor? Portable SpO2 Patient Monitoring System
Covidien, a leading global provider of health care products and recognized innovator in patient monitoring and respiratory care devices, today announced CE Mark and the launch of the Nellcor™ Portable SpO2 Patient Monitoring System (PM10N).
Available now throughout the European Economic Area, this handheld monitor is simple to use and provides continuous and spot-check monitoring of blood oxygenation (SpO2) and pulse rate, along with trend data to help clinicians detect and respond to dangerous respiratory events quickly.
The Nellcor™ Portable SpO2 Patient Monitoring System is the only commercially available portable oximeter equipped with home care and sleep study modes and which complies with IEC 60601-1-11 standards for devices used in the home health care environment.
“With this new generation of portable pulse oximeters, Covidien is incorporating state-of-the-art technology to address critical patient issues, such as respiratory compromise and alarm management – all through a convenient, handheld design,” said Matt Anderson, vice president & general manager, Patient Monitoring, Covidien. “We continuously strive to develop new technology that both enhances and simplifies patient care. This new monitor is easy to use and brings our reliable pulse oximetry technology to patients both inside and out of the hospital.”
The lightweight system is user-friendly and features a home care mode that expands the utility of the monitor beyond the hospital to home-use environments. With a simplified user interface, patients can clearly view their vital sign readings, and the settings cannot easily be altered by the patient, so clinicians can feel confident prescribing the home-use of this monitor. The system also features a sleep study mode that enables dimming of the LCD display and silencing of alarms to prevent disrupting patients’ sleep.
The SatSeconds™ alarm management feature helps differentiate between serious and minor events, reducing clinically insignificant desaturation alarms and alarm fatigue.
The monitor incorporates Nellcor™ digital signal processing technology which relies on cardiac-based signals to provide accurate readings that are closely tied to the patient’s physiology. The result is consistent performance during a number of challenging conditions, including patient motion, noise and low perfusion – all of which can impede the assessment of patient respiratory status.
The ability to perform in challenging conditions, combined with a portable and convenient design, makes the Nellcor™ Portable SpO2 Patient Monitoring System an ideal solution for a number of critical screenings, including:
- Six Minute Walk Test – Used to provide an objective measurement of a patient’s exercise capacity, this test evaluates the response of all systems involved during exercise including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism.
- Critical Congenital Heart Disease (CCHD) Screening – In the United States alone, about 4,800 (or 11.6 per 10,000) babies are born every year with CCHD. These babies are at significant risk if this condition goes undiagnosed.1 Since 1993, Nellcor™ pulse oximetry technology has been utilized on more than 33,000 newborns spanning five separate clinical studies evaluating the use of pulse oximetry for critical congenital heart disease screening.2-6
- Car Seat Challenge Test – According to the American Academy of Pediatrics guidelines, as part of the discharge process, each preterm infant born less than 37 weeks gestational age should have a period of observation in a car safety seat before hospital discharge to monitor for possible apnea, bradycardia or oxygen desaturation7.
“Clinicians can feel confident using the Nellcor Portable SpO2 Patient Monitoring System for these important patient assesments,” said Dr. Scott Kelley, chief medical officer, Respiratory and Monitoring Solutions, Covidien. “Because our pulse oximetry technology relies on cardiac signals, it mitigates signal interference, offering caregivers peace of mind. They can count on our technology to provide accurate patient data, even during difficult conditions.”
More information on the product portfolio is available by visiting www.Covidien.com/PM10N.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.
1. Centers for Disease Control and Prevention. Pulse Oximetry Screening for Critical Congenital Heart Defects. Available at: http://www.cdc.gov/ncbddd/pediatricgenetics/CCHDscreening.html.
2. Hoke, T.R., et al., Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study. Pediatr Cardiol, 2002 Jul-Aug. 23(4): p. 403-9.
3. Reich, J.D., et al., The use of pulse oximetry to detect congenital heart disease. J Pediatr, 2003 Mar. 142(3): p. 268-72.
4. Arlettaz, R., et al., The contribution of pulse oximetry to the early detection of congenital heart disease in newborns. Eur J Pediatr, 2006 Feb. 165(2): p. 94-8.
5. Sendelbach, D.M., et al., Pulse oximetry screening at 4 hours of age to detect critical congenital heart defects. Pediatrics, 2008 Oct. 122(4): p. e815-20.
6. Walsh, W., Evaluation of pulse oximetry screening in Middle Tennessee: cases for consideration before universal screening. J Perinatol, 2011 Feb. 31(2): p. 125-9.